CTDH - Cyclo Therapeutics on go with enrollment in late-stage study with lead asset

The FDA has signed-off Phase 3 trial evaluating Cyclo Therapeutics's ([[CTDH]] +8.0%) lead candidate Trappsol Cyclo (Hydroxypropyl-?-cyclodextrin), for the treatment of Niemann-Pick Disease Type C, a rare inherited disorder in which the body is unable to transport cholesterol and other lipids inside of cells. The fatty substances accumulate in various body tissues, leading to potentially life-threatening nerve and organ damage.The trial will evaluate the safety, tolerability, and efficacy of Trappsol Cyclo and standard of care compared to Placebo.The drug candidate is an orphan drug in the U.S. and EuropeThe company is planning an early phase clinical trial using Trappsol Cyclo intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease.

For further details see:

Cyclo Therapeutics on go with enrollment in late-stage study with lead asset